Harbor Capital Advisors, Inc. Autolus Therapeutics PLC Transaction History

Harbor Capital Advisors, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$5.39 - $7.29 $154,595 - $209,091	-28,682 Reduced 9.3%	279,820 $1.79 Million
Q4 2023 Jan 08, 2024	BUY	$2.13 - $6.63 $47,790 - $148,757	22,437 Added 7.84%	308,502 $1.99 Million
Q3 2023 Oct 20, 2023	BUY	$2.32 - $3.36 $96,335 - $139,520	41,524 Added 16.98%	286,065 $666,000
Q2 2023 Jul 11, 2023	BUY	$1.64 - $3.21 $36,722 - $71,878	22,392 Added 10.08%	244,541 $582,000
Q1 2023 Apr 26, 2023	BUY	$1.75 - $2.25 $134,459 - $172,876	76,834 Added 52.87%	222,149 $408,000
Q4 2022 Jan 20, 2023	SELL	$1.74 - $3.27 $5,461 - $10,264	-3,139 Reduced 2.11%	145,315 $0
Q3 2022 Oct 28, 2022	SELL	$2.04 - $3.76 $33,562 - $61,859	-16,452 Reduced 9.98%	148,454 $318,000
Q2 2022 Jul 26, 2022	BUY	$2.04 - $4.68 $3,596 - $8,250	1,763 Added 1.08%	164,906 $467,000
Q1 2022 Apr 28, 2022	SELL	$3.52 - $5.46 $169,579 - $263,040	-48,176 Reduced 22.8%	163,143 $680,000
Q4 2021 Feb 04, 2022	BUY	$5.1 - $7.0 $1.08 Million - $1.48 Million	211,319 New	211,319 $1.1 Million

104

163M

2.8K

13.4K

Ticker AUTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,909,800
Market Cap $205M
Description
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...

Get notified when there are updates to the investment portfolio of Harbor Capital Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Harbor Capital Advisors, Inc. with notifications on news.